埃博拉快速诊断试剂
美国一家公司发明了一种新型埃博拉病毒检测设备，它可以帮助疾控部门在数分钟之内就能检测出埃博拉病毒，从而有效地防止病毒的扩散。这一检测设备只需要从指尖抽取几滴血液样本，就能快速进行检测，而且最大限度减少了医护人员接触血液样本的机会，从而降低了医护人员感染病毒的危险。检测结果可以媲美需要耗时数天的传统医学化验。
这种检测跟早孕测试笔的工作原理差不多，可以通过检测条上的颜色变化，快速判断出病毒的存在。如果被检测的血液中含有埃博拉病毒，那么在检测条上会有很明显的颜色变化显示。
类似于家用早孕检测试纸，如果埃博拉病毒呈阳性，在特定位置就会出现彩色线条
这一设备的发明给医护人员省了大力。现在的埃博拉病毒检测，需要建设专门的检测试验室，而且需要在采集大量血液标本后，再进行长距离的运输，这样不但费时费力，还增加了医护人员感染埃博拉病毒的几率。更为重要的是，使用此种设备后，因为化验时间的提升、人力的降低，可以更快的隔离被感染病患，从而十分有效的进行早期治疗，不但降低了病死率，而且能够很高效的防止病毒的大面积传播。
目前，在塞拉利昂卫生部直属的两家医疗中心，这种检测设备的测试工作正在进行中，实验由美国Corgenix公司进行。
已经有106名疑似埃博拉病毒感染者接受了手部采血测试，测试结果将与通过传统检测方式得出的结果进行对比，以测试这一检测的准确性 。
实验结果非常令人满意，用新测试方法检测出的每一例埃博拉病毒携带者，都得到了传统检测方式所得出结果的验证。只有极少数人未被埃博拉病毒感染，而被错误地检测为病毒携带者。
有些遗憾的是，两种检测方法均未检出一小部分埃博拉病毒的携带者。这一部分携带者是由一种未被普遍应用的检测方式检出的。
参与测试的美国波士顿儿童医院医生Nira Pollock说：“缩短和加快病毒的检测过程，对埃博拉病毒的防控会产生极大的影响。”
这一设备的名称为“ReEBOV抗原快速检测”设备，是由Corgenix公司研制的。
来源：蝌蚪五线谱 Product Overview
The ReEBOV Antigen Rapid Test is a point-of-care assay intended to quickly diagnose EBV in patients with signs and symptoms who may have been exposed to the Ebola virus.
According to the manufacturer, the test is a dipstick immunoassay intended to detect the presence of the VP40 antigen from Ebola virus strains Zaire, Sudan, and Bundibugyo. The Ebola Zaire strain is the strain detected in the West Africa 2014 outbreak. The assay is run on whole blood samples obtained from a fingerstick sample or venous draw or on plasma samples. (See link to the manufacturer's IFU under Selected References and Resources.) Test results can be obtained within 15 to 25 minutes. Test results are qualitative rather than quantitative and do not indicate the severity or stage of EBV infection. The assay is packaged with test dipsticks, sample buffer, both negative and positive controls (negative human serum; VP40 antigen-spiked negative human serum), test tubes and rack, and a ReEBOV Rapid Test Results Card. The card is used to interpret the test results that appear on the dipstick or to determine whether the test result is invalid. The test reagents should be kept under refrigeration (2o to 8oC) and should not be frozen. (See link to the manufacturer's IFU under Selected References and Resources.)
The test is described as being less sensitive than an Ebola nucleic acid test and may return both false positives and false negatives. This assay is not intended for, or approved for, use in general EBV screening. Additionally, the assay is intended for use only in individuals who meet "clinical and epidemiologic criteria for testing suspect specimens."
Purported Benefits/Advantages According to Manufacturers' Information*
" is designed to be used in any clinical or field lab to determine in a matter of minutes if a patient is infected with Ebola."
"A positive test result from the ReEBOV™ Antigen Rapid Test indicates that the patient is presumptively infected with Ebola Zaire virus."
"The ReEBOV™ Antigen Rapid Test has been designed to minimize the likelihood of false positive test results."
"A negative test presumes that Ebola virus …was not present at the detection level of the assay. However, negative results do not preclude Ebola virus infection, and should not be used as the sole basis for treatment, public health, or other patient management decisions."
*Note: This is a list of the main benefits described by the manufacturer and does not imply endorsement or validation by ECRI Institute.
https://www.ecri.org/components/ProductBriefs/Pages/23488.aspx?tab=2 不就是胶体金么？
页:
[1]